MedTrace Logo

Prevention of Heterotopic Ossification With Arcoxia After Total Hip Replacement

NCT01022190 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2013-09-09

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine whether Arcoxia is effective in preventing heterotopic ossification after total hip arthroplasty.

Conditions

  • Ossification, Heterotopic

Interventions

DRUG

Etoricoxib (Arcoxia)

Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • R.P.H. Veth, Prof, MD · Radboud University Nijmegen Medical Centre, department of Orthopedics

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01022190 on ClinicalTrials.gov